Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy pipeline. Double Point Ventures and DCVC Bio jointly led the round, with...
Bayer’s experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test for regenerative medicine in neurologic conditions. The therapy, known as bemdaneprocel, is being developed by BlueRock Therapeutics, a Bayer...
US-based biotech company A2 Biotherapeutics (A2 Bio) has secured $80m in funding to advance its pipeline of chimeric antigen receptor (CAR)-T cell therapies for solid tumour cancers. The Series C financing, backed by investors such as The Column Group and Samsara...
The Biden Administration said Wednesday that it has secured agreements with Vertex Pharmaceuticals and bluebird bio for their sickle cell disease gene therapies to be the first in a new access model from the Centers for Medicare and Medicaid Services. The voluntary...
Collaboration will combine Vyriad’s lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ROCHESTER, Minn., Nov. 20, 2024 /PRNewswire/ — Vyriad, Inc., a clinical-stage biotechnology company developing the next...